Revolution Medicines (RVMD) Other financing activities (2019 - 2026)

Revolution Medicines' Other financing activities history runs 8 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 1220800.0% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $33.3 million, a 65.06% decrease from a year earlier, with the FY2025 full-year figure at $21.1 million, down 77.85% from the prior year.
• Other financing activities slipped to $12.2 million in Q1 2026 per RVMD's latest filing, from $14.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $87.3 million in Q4 2024 and bottomed at -$2.0 million in Q4 2023.
• The 5-year median for Other financing activities is $894000.0 (2022), against an average of $8.1 million.
• Across the five-year window, Other financing activities plunged 354.57% in 2023 and surged 1220800.0% in 2026, its largest moves.
• Year by year, Other financing activities stood at $777000.0 in 2022, then plunged by 354.57% to -$2.0 million in 2023, then jumped by 4512.08% to $87.3 million in 2024, then tumbled by 83.77% to $14.2 million in 2025, then fell by 13.78% to $12.2 million in 2026.
• Per Business Quant, the three latest RVMD Other financing activities figures stand at $12.2 million (Q1 2026), $14.2 million (Q4 2025), and $4.1 million (Q3 2025).